Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial

被引：0

作者：

F. J. Esteva

Y. V. Baranau

V. Baryash

A. Manikhas

V. Moiseyenko

G. Dzagnidze

E. Zhavrid

D. Boliukh

D. Stroyakovskiy

J. Pikiel

A. E. Eniu

R. K. Li

A. V. Rusyn

B. Tiangco

S. J. Lee

S. Young Lee

S. Y. Yu

J. Stebbing

机构：

[1] NYU Langone Health,Perlmutter Cancer Center

[2] New York University Langone Medical Center,Department of Oncology

[3] Belarusian State Medical University,Division of Cancer

[4] City Clinical Oncology Dispensary,Imperial College Healthcare NHS Trust

[5] GBUZ Saint Petersburg Clinical Research Center of Specialised Types of Care (Oncology),undefined

[6] S. Khechinashvili University Clinic,undefined

[7] Ltd,undefined

[8] N.N. Alexandrov National Cancer Centre of Belarus,undefined

[9] Vinnytsya Regional Clinical Oncology Dispensary,undefined

[10] Moscow City Oncology Hospital,undefined

[11] Wojewodzkie Centrum Onkologii,undefined

[12] Cancer Institute “Ion Chiricuta”,undefined

[13] St. Luke’s Medical Center,undefined

[14] Transcarpathian Regional Clinical Oncology Dispensary,undefined

[15] The Medical City,undefined

[16] CELLTRION,undefined

[17] Inc.,undefined

[18] Imperial Centre for Translational and Experimental Medicine,undefined

[19] Charing Cross Hospital,undefined

来源：

Cancer Chemotherapy and Pharmacology | 2019年 / 84卷

关键词：

Trastuzumab; Biosimilar; CT-P6; HER2 positive; Adjuvant; Breast cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：839 / 847

页数：8

共 50 条

[1] Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
Esteva, F. J.
Baranau, Y. V.
Baryash, V.
Manikhas, A.
Moiseyenko, V.
Dzagnidze, G.
Zhavrid, E.
Boliukh, D.
Stroyakovskiy, D.
Pikiel, J.
Eniu, A. E.
Li, R. K.
Rusyn, A. V.
Tiangco, B.
Lee, S. J.
Lee, S. Young
Yu, S. Y.
Stebbing, J.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 839 - 847
[2] Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
Stebbing, Justin
Baranau, Yauheni, V
Baryash, Valery
Manikhas, Alexey
Moiseyenko, Vladimir
Dzagnidze, Giorgi
Zhavrid, Edvard
Boliukh, Dmytro
Pikiel, Joanna
Eniu, Alexandru E.
Li, Rubi K.
Tiangco, Beatrice
Lee, Sang Joon
Kim, Sunghyun
BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (03) : 631 - 640
[3] Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
Justin Stebbing
Yauheni V. Baranau
Valery Baryash
Alexey Manikhas
Vladimir Moiseyenko
Giorgi Dzagnidze
Edvard Zhavrid
Dmytro Boliukh
Joanna Pikiel
Alexandru E. Eniu
Rubi K. Li
Beatrice Tiangco
Sang Joon Lee
Sunghyun Kim
Breast Cancer Research and Treatment, 2021, 188 : 631 - 640
[4] CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
Stebbing, Justin
Baranau, Yauheni
Baryash, Valeriy
Manikhas, Alexey
Moiseyenko, Vladimir
Dzagnidze, Giorgi
Zhavrid, Edvard
Boliukh, Dmytro
Stroyakovskii, Daniil
Pikiel, Joanna
Eniu, Alexandru
Komov, Dmitry
Morar-Bolba, Gabriela
Li, Rubi K.
Rusyn, Andriy
Lee, Sang Joon
Lee, Sung Young
Esteva, Francisco J.
LANCET ONCOLOGY, 2017, 18 (07): : 917 - 928
[5] Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer A Retrospective Analysis
Park, Joo-Hwan
Yeo, Ja Hyun
Kim, Young Saing
Park, Inkeun
Ahn, Hee Kyung
Cho, Eun Kyung
Shin, Dong Bok
Yang, Jun-Young
Kim, Hyung-Sik
Lee, Woon Kee
Sym, Sun Jin
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (02): : 61 - 65
[6] Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data
Bernat-Peguera, Adria
Trigueros, Macedonia
Ferrando-Diez, Angelica
Ibanez, Cristina
Bystrup, Sara
Martinez-Cardus, Anna
Margeli, Mireia
Martinez-Balibrea, Eva
BREAST, 2022, 62 : 1 - 9
[7] Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Stebbing, Justin
Baranau, Yauheni
Baryash, Valery
Moiseyenko, Vladimir
Boliukh, Dmytro
Antone, Nicoleta
Manikhas, Alexey
Chornobai, Anatolii
Park, Taehong
Baek, Eric Hyungseok
Lee, Jaeyong
Choi, Jiin
Kim, Nahyun
Ahn, Keumyoung
Lee, Sang Joon
Kim, Sunghyun
BIODRUGS, 2023, 37 (03) : 433 - 440
[8] Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial
Xu, Binghe
Zhang, Qingyuan
Sun, Tao
Li, Wei
Teng, Yue'e
Hu, Xichun
Bondarenko, Igor
Adamchuk, Hryhoriy
Zhang, Liangming
Trukhin, Dmytro
Wang, Shusen
Zheng, Hong
Tong, Zhongsheng
Shparyk, Yaroslav
Yang, Futang
Yu, Haoyu
Li, Jing
Wang, Qingyu
Zhu, Jun
BREAST, 2025, 80
[9] Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial
Justin Stebbing
Yauheni Baranau
Valery Baryash
Vladimir Moiseyenko
Dmytro Boliukh
Nicoleta Antone
Alexey Manikhas
Anatolii Chornobai
Taehong Park
Eric Hyungseok Baek
Jaeyong Lee
Jiin Choi
Nahyun Kim
Keumyoung Ahn
Sang Joon Lee
Sunghyun Kim
BioDrugs, 2023, 37 : 433 - 440
[10] Long-term efficacy of trastuzumab biosimilar CT-P6 in patients with HER2-positive early breast cancer: 6-year survival analysis of phase III study results
Stebbing, J.
Baranau, Y.
Baryash, V.
Moiseyenko, V.
Boliukh, D.
Antone, N. Z.
Manikhas, A.
Chornobai, A.
Kim, S. H.
Ahn, K.
Park, T.
Baek, E. H.
Park, S.
Lee, S. J.
Chang, I. S.
Kim, S. H.
Lee, J. Y.
Choi, J. I.
ANNALS OF ONCOLOGY, 2022, 33 : S212 - S213

← 1 2 3 4 5 →